BioSpace News Archive

With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that process.

Innate Pharma SA announced that the first patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab, in COVID-19 patients with severe pneumonia.

R-Pharm JSC and Cromos Pharma announced that it has randomized the first patients into a clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19 infection.

Prokarium is pleased to announce it has signed an exclusive, worldwide Option Agreement with the Lausanne University Hospital - CHUV, a Switzerland-based research hospital, to acquire a license to cover the treatment of Non-Muscle Invasive Bladder Cancer patients with intravesical instillations of Salmonella.

A formal adoption of outstanding questions, incl. definition of patients and design of the post approval study, expected at the CHMP April session

Dr. Alberico Sessa Decreases Facelift Scarring And Recovery Time With Revolutionary SmartLift™.

First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Revenues Declined 1% Operationally

The designation is for L‑CsA‑i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company.

TherapeuticsMD, Inc., an innovative women’s healthcare company, announced that it will report its first quarter 2020 financial results on Wednesday, May 6, 2020, before the opening of the U.S. financial markets.

First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%; Excluding the Impact from Foreign Exchange, Sales Grew 13%